發(fā)布時(shí)間：2018-03-28 08:04

  本文選題：醫(yī)療機(jī)構(gòu)　切入點(diǎn)：醫(yī)療機(jī)構(gòu)制劑　出處：《南京中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：醫(yī)療機(jī)構(gòu)制劑是我國特有的概念,其產(chǎn)生與發(fā)展的原因與我國的基本國情息息相關(guān)。在建國初期缺醫(yī)少藥的大背景下,醫(yī)療機(jī)構(gòu)制劑對(duì)維護(hù)國民健康、支持我國醫(yī)療衛(wèi)生事業(yè)發(fā)展做出的貢獻(xiàn)不容置疑。經(jīng)過建國以來60多年的發(fā)展,我國的醫(yī)藥工業(yè)已經(jīng)煥然一新,藥品供應(yīng)體系也已經(jīng)基本建立。但是醫(yī)療機(jī)構(gòu)制劑治療疾病方面仍起著不可取代的作用。在社會(huì)大眾對(duì)藥品安全性關(guān)注日益提高的大背景下,國家法律法規(guī)對(duì)其的要求也越來越嚴(yán)格,這也使得新時(shí)期我國醫(yī)療機(jī)構(gòu)制劑的發(fā)展出現(xiàn)了新特點(diǎn)。 本研究在闡述江蘇省醫(yī)療機(jī)構(gòu)制劑發(fā)展和監(jiān)管歷史的基礎(chǔ)上,對(duì)醫(yī)療機(jī)構(gòu)制劑配制、使用和監(jiān)管現(xiàn)狀開展定性研究和定量研究。首先,選取江蘇省具有制劑許可證的醫(yī)療機(jī)構(gòu)作為研究對(duì)象,搜集制劑配制許可證、醫(yī)療機(jī)構(gòu)制劑批準(zhǔn)文號(hào)以及醫(yī)療機(jī)構(gòu)制劑再注冊(cè)等有關(guān)材料；其次,對(duì)江蘇省醫(yī)療機(jī)構(gòu)制劑基本情況進(jìn)行調(diào)研,并對(duì)醫(yī)療機(jī)構(gòu)制劑安全性監(jiān)測(cè)現(xiàn)狀進(jìn)行專家訪談；最后,通過SWOT-PEST分析得出江蘇省醫(yī)療機(jī)構(gòu)制劑現(xiàn)狀存在問題以及監(jiān)管中的不足,并進(jìn)而提出相關(guān)的對(duì)策建議。 通過本研究可以得出目前江蘇省醫(yī)療機(jī)構(gòu)制劑的一般結(jié)果：醫(yī)療機(jī)構(gòu)制劑室數(shù)量在逐年減少,逐漸趨于合理；醫(yī)療機(jī)構(gòu)制劑批準(zhǔn)文號(hào)數(shù)量在大幅度減少,基本符合醫(yī)療機(jī)構(gòu)制劑定位；醫(yī)療機(jī)構(gòu)制劑室人員數(shù)量不足,專業(yè)素質(zhì)普遍不高；醫(yī)療機(jī)構(gòu)制劑研發(fā)資金投入少,研發(fā)水平不高；醫(yī)療機(jī)構(gòu)制劑不良反應(yīng)率逐漸降低,但不良反應(yīng)監(jiān)測(cè)和再評(píng)價(jià)仍需加強(qiáng)；醫(yī)療機(jī)構(gòu)中藥制劑委托加工應(yīng)加強(qiáng)管理；醫(yī)療機(jī)構(gòu)制劑加入醫(yī)保范圍仍需加大；醫(yī)療機(jī)構(gòu)制劑配制質(zhì)量管理規(guī)范的實(shí)施,制劑質(zhì)量與安全性得到了提高；醫(yī)療機(jī)構(gòu)制劑原料檢驗(yàn)遠(yuǎn)遠(yuǎn)達(dá)不到要求；醫(yī)療機(jī)構(gòu)制劑監(jiān)督管理體系仍需完善。
[Abstract]:Medical institution preparation is a unique concept in our country, and the reasons for its emergence and development are closely related to the basic conditions of our country. In the background of lack of medical and minor medicine in the early days of the founding of the people's Republic of China, medical institution preparations have a great impact on the maintenance of national health. The contribution of supporting the development of medical and health care in our country is beyond doubt. After more than 60 years of development since the founding of the people's Republic of China, the pharmaceutical industry in our country has taken on a new look. The drug supply system has also been basically established. But medical institutions still play an irreplaceable role in the treatment of diseases. Against the background of increasing public concern about drug safety, The requirements of national laws and regulations are more and more strict, which makes the development of medical institutions in our country appear new characteristics in the new period. On the basis of expounding the history of preparation development and supervision of medical institutions in Jiangsu Province, this study carries out qualitative and quantitative studies on the present situation of preparation, use and supervision of formulations in medical institutions. Selecting the medical institutions with preparation license in Jiangsu Province as the research object, collecting the preparation license, the approval number of the preparation of the medical institution and the re-registration of the preparation of the medical institution. Secondly, To investigate the basic situation of medical institutions in Jiangsu Province, and to conduct expert interviews on the status quo of safety monitoring of medical institutions. Finally, through SWOT-PEST analysis, we can conclude that the current situation of medical institutions in Jiangsu Province has problems and deficiencies in supervision. And then put forward the relevant countermeasures and suggestions. Through this study, we can get the general results of the preparation of medical institutions in Jiangsu Province: the number of preparation rooms in medical institutions is decreasing year by year, and gradually tending to be reasonable, and the number of approved documents for medical institutions is greatly reduced. It is basically in line with the orientation of medical institutions; the number of personnel in the preparation rooms of medical institutions is insufficient, and the professional quality is generally not high; the investment in R & D of medical institutions is low, and the level of R & D is not high; the adverse reaction rate of medical institutions is gradually decreasing. However, the monitoring and re-evaluation of adverse reactions should be strengthened; the commissioning and processing of traditional Chinese medicine preparations in medical institutions should be strengthened; the scope of medical institutions' preparations added to medical insurance still need to be enlarged; and the implementation of quality management norms for the preparation of medical institutions' preparations, The quality and safety of the preparation have been improved; the raw material inspection of the preparation in medical institutions is far from meeting the requirements; the supervision and management system of the preparation in the medical institutions still needs to be improved.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R95

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳艷,柴國仁;淺析新形勢(shì)下醫(yī)院制劑的現(xiàn)狀和發(fā)展方向[J];安徽醫(yī)藥;2001年04期

2 陶韜;潘明陽;;淺談醫(yī)院制劑的現(xiàn)狀與發(fā)展趨勢(shì)[J];東南國防醫(yī)藥;2009年02期

3 陳文林;馬傳學(xué);;淺析新形勢(shì)下醫(yī)院制劑的現(xiàn)狀及發(fā)展方向[J];海峽藥學(xué);2005年06期

4 曾白林;;醫(yī)院中藥制劑的現(xiàn)狀與發(fā)展對(duì)策探討[J];江蘇中醫(yī)藥;2010年06期

5 孫益新;張永;;對(duì)我院醫(yī)院制劑生產(chǎn)及使用情況的探討[J];求醫(yī)問藥(下半月);2013年12期

6 趙莉;我市醫(yī)院普通制劑的質(zhì)量現(xiàn)狀與對(duì)策[J];山東醫(yī)藥工業(yè);1996年02期

7 陳怡祿,黃躍,何潤敏;論兒童醫(yī)院制劑的存在與發(fā)展前景[J];廣東藥學(xué);2003年04期

8 曹立亞;張承緒;郭曉昕;吳曄;程魯榕;;關(guān)于我國藥品上市后評(píng)價(jià)技術(shù)工作的思考[J];中國藥物警戒;2006年01期

9 蘇祥熙;醫(yī)院制劑的現(xiàn)狀與發(fā)展趨勢(shì)[J];江蘇藥學(xué)與臨床研究;2001年01期

10 孫駿;郭立瑋;王繁可;王佳域;;分析江蘇省醫(yī)療機(jī)構(gòu)制劑許可證現(xiàn)狀探討制劑室的發(fā)展方向[J];藥學(xué)與臨床研究;2009年03期

，

本文編號(hào)：1675451